🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 13 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 21/05/1997 | 17,50 | 17,63 | 17,00 | 17,13 | -0,72% | 3,57% | 168.200 |
| 20/05/1997 | 17,00 | 17,50 | 17,00 | 17,25 | -0,72% | 2,94% | 328.000 |
| 19/05/1997 | 17,13 | 17,69 | 16,88 | 17,38 | +2,21% | 4,74% | 176.400 |
| 16/05/1997 | 16,69 | 17,38 | 16,69 | 17,00 | -0,73% | 4,12% | 324.800 |
| 15/05/1997 | 17,16 | 17,38 | 16,63 | 17,13 | -0,72% | 4,37% | 287.600 |
| 14/05/1997 | 17,06 | 17,63 | 16,88 | 17,25 | +1,47% | 4,40% | 377.000 |
| 13/05/1997 | 16,75 | 17,13 | 16,75 | 17,00 | +0,74% | 2,24% | 937.600 |
| 12/05/1997 | 17,63 | 17,63 | 16,63 | 16,88 | -0,74% | 5,67% | 118.600 |
| 09/05/1997 | 18,13 | 18,13 | 16,94 | 17,00 | -6,21% | 6,55% | 310.400 |
| 08/05/1997 | 17,94 | 18,25 | 17,88 | 18,13 | +1,40% | 2,09% | 772.600 |
| 07/05/1997 | 18,44 | 18,44 | 17,56 | 17,88 | -1,38% | 4,75% | 462.600 |
| 06/05/1997 | 18,13 | 18,88 | 17,88 | 18,13 | +1,40% | 5,52% | 1.077.600 |
| 05/05/1997 | 17,38 | 18,69 | 17,00 | 17,88 | +6,32% | 9,71% | 2.064.800 |
| 02/05/1997 | 15,25 | 16,88 | 15,13 | 16,81 | +10,25% | 11,48% | 1.618.000 |
| 01/05/1997 | 15,88 | 15,88 | 14,88 | 15,25 | -3,94% | 6,30% | 603.800 |
| 30/04/1997 | 15,25 | 16,00 | 15,00 | 15,88 | +4,10% | 6,56% | 681.200 |
| 29/04/1997 | 14,88 | 15,38 | 14,63 | 15,25 | +7,02% | 5,04% | 901.400 |
| 28/04/1997 | 15,00 | 15,25 | 14,13 | 14,25 | -5,00% | 7,50% | 746.200 |
| 25/04/1997 | 16,13 | 16,13 | 13,81 | 15,00 | -4,95% | 14,34% | 2.021.600 |
| 24/04/1997 | 16,50 | 16,56 | 15,75 | 15,78 | -3,63% | 4,92% | 685.600 |
| 23/04/1997 | 17,50 | 17,50 | 16,31 | 16,38 | -5,07% | 6,79% | 435.600 |
| 22/04/1997 | 16,75 | 17,38 | 16,63 | 17,25 | +3,76% | 4,48% | 245.600 |
| 21/04/1997 | 17,38 | 17,63 | 16,38 | 16,63 | -3,62% | 7,19% | 538.600 |
| 18/04/1997 | 16,25 | 17,38 | 16,00 | 17,25 | +6,15% | 8,46% | 1.352.000 |
| 17/04/1997 | 17,25 | 17,50 | 16,00 | 16,25 | -5,11% | 8,70% | 1.389.600 |
| 16/04/1997 | 18,75 | 18,88 | 17,00 | 17,13 | -8,36% | 10,00% | 517.800 |
| 15/04/1997 | 19,13 | 19,75 | 18,50 | 18,69 | +0,34% | 6,54% | 349.200 |
| 14/04/1997 | 19,63 | 19,63 | 18,25 | 18,63 | -4,49% | 7,01% | 410.000 |
| 11/04/1997 | 20,50 | 21,25 | 19,38 | 19,50 | -6,02% | 9,15% | 849.400 |
| 10/04/1997 | 20,38 | 21,06 | 19,63 | 20,75 | +0,61% | 7,06% | 414.600 |